143 related articles for article (PubMed ID: 10726064)
1. Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan.
Iino S
Antivir Ther; 1998; 3(Suppl 3):143-6. PubMed ID: 10726064
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
4. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
5. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Soga K; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
7. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
8. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
9. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
10. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
11. Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.
Hino K; Okita K
J Antimicrob Chemother; 2004 Jan; 53(1):19-22. PubMed ID: 14657083
[TBL] [Abstract][Full Text] [Related]
12. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
13. A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia.
Hayashi J; Furusyo N; Ariyama I; Sawayama Y; Etoh Y; Kashiwagi S
J Infect Dis; 2000 May; 181(5):1523-7. PubMed ID: 10823749
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
[TBL] [Abstract][Full Text] [Related]
15. Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan.
Ishiguro S; Inoue M; Tanaka Y; Mizokami M; Iwasaki M; Tsugane S;
Eur J Cancer Prev; 2009 Feb; 18(1):26-32. PubMed ID: 19077561
[TBL] [Abstract][Full Text] [Related]
16. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
[TBL] [Abstract][Full Text] [Related]
17. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
18. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
[TBL] [Abstract][Full Text] [Related]
19. Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic hepatitis C.
Imazeki F; Yokosuka O; Fukai K; Kawai S; Kanda T; Kojima H; Saisho H
Liver Int; 2005 Aug; 25(4):772-8. PubMed ID: 15998428
[TBL] [Abstract][Full Text] [Related]
20. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.
Miyakawa K; Tarao K; Ohshige K; Morinaga S; Ohkawa S; Okamoto N; Shibuya A; Adachi S; Miura Y; Fujiyama S; Miyase S; Tomita K
Scand J Gastroenterol; 2009; 44(11):1340-8. PubMed ID: 19891585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
